1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Alcoholic Hepatitis Treatment Market: About this market
Alcoholic hepatitis is inflammation of the liver, which is caused due to the heavy drinking of alcohol. This alcoholic hepatitis treatment market analysis considers sales from different types of treatments, including corticosteroids, xanthine derivatives, and others. Our analysis also considers the sales of alcoholic hepatitis treatment in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of combination therapies will play a significant role in the corticosteroids segment to maintain its market position. Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies. However, lack of therapies to treat severe alcoholic hepatitis, side effects associated with drugs used to treat alcoholic hepatitis, and availability of alternative therapies may hamper the growth of the alcoholic hepatitis treatment industry over the forecast period.
Global Alcoholic Hepatitis Treatment market: Overview
Increasing consumption of alcohol worldwide
Heavy alcohol consumption leads to hepatic encephalopathy and high mortality rates. This has created an opportunity for vendors to launch off-label therapies and corticosteroids in the market. The increasing demand for these drugs will lead to the expansion of the global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period.
Development of novel targets and viable treatment options for the management of alcoholic hepatitis
Vendors are heavily investing in the development of novel targets and viable treatment options due to the lack of effective treatments for severe alcoholic hepatitis. Also, certain novel drugs developed by them are under clinical trials. This further creates growth opportunities for vendors, which is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few major players, the global alcoholic hepatitis treatment market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alcoholic hepatitis treatment manufacturers, that include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.
Also, the alcoholic hepatitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Alcoholic hepatitis is inflammation of the liver, which is caused due to the heavy drinking of alcohol. This alcoholic hepatitis treatment market analysis considers sales from different types of treatments, including corticosteroids, xanthine derivatives, and others. Our analysis also considers the sales of alcoholic hepatitis treatment in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of combination therapies will play a significant role in the corticosteroids segment to maintain its market position. Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies. However, lack of therapies to treat severe alcoholic hepatitis, side effects associated with drugs used to treat alcoholic hepatitis, and availability of alternative therapies may hamper the growth of the alcoholic hepatitis treatment industry over the forecast period.
Global Alcoholic Hepatitis Treatment market: Overview
Increasing consumption of alcohol worldwide
Heavy alcohol consumption leads to hepatic encephalopathy and high mortality rates. This has created an opportunity for vendors to launch off-label therapies and corticosteroids in the market. The increasing demand for these drugs will lead to the expansion of the global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period.
Development of novel targets and viable treatment options for the management of alcoholic hepatitis
Vendors are heavily investing in the development of novel targets and viable treatment options due to the lack of effective treatments for severe alcoholic hepatitis. Also, certain novel drugs developed by them are under clinical trials. This further creates growth opportunities for vendors, which is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few major players, the global alcoholic hepatitis treatment market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alcoholic hepatitis treatment manufacturers, that include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.
Also, the alcoholic hepatitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits:
Note: Product cover images may vary from those shown
The following companies are recognised as the key players in the global alcoholic hepatitis treatment market: Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel targets and viable treatment options for the management of alcoholic hepatitis.”
According to the report, one of the major drivers for this market is the increasing consumption of alcohol worldwide.
Further, the report states that one of the major factors hindering the growth of this market is the availability of alternative therapies.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel targets and viable treatment options for the management of alcoholic hepatitis.”
According to the report, one of the major drivers for this market is the increasing consumption of alcohol worldwide.
Further, the report states that one of the major factors hindering the growth of this market is the availability of alternative therapies.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Apotex Inc.
- Gilead Sciences Inc.
- Johnson & Johnson Services Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown